[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100568092":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":48,"collaborators":19,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":19,"eligibilityCriteria":58,"healthyVolunteers":59,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":19,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":19,"overallStatus":41,"whyStopped":19,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"The First Affiliated Hospital of Xiamen University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental","EXPERIMENTAL","SBRT combined with Nimotuzumab followed by Tislelizumab",[13],"Drug: SBRT combined with Nimotuzumab followed by Tislelizumab",[15],{"type":16,"name":11,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","BRT combined with 3 cycles of Nimotuzumab 400mg qw followed by maintain Tislelizumab for 2 years or until disease progression",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"San-Gang Wu, MD., PHD","CONTACT","865922139531","wusg@xmu.edu.cn",[27,40],{"facility":5,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":19},"ENROLLING_BY_INVITATION","Xiamen","Fujian","361003","China","CN",{"type":35,"coordinates":36},"Point",[37,38],118.08187,24.47979,{"lat":38,"lon":37},{"facility":5,"status":41,"city":29,"state":30,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":42,"geoPoint":44,"contacts":45},"RECRUITING",{"type":35,"coordinates":43},[37,38],{"lat":38,"lon":37},[46],{"name":47,"role":23,"phone":24,"phoneExt":19,"email":25},"San-Gang Wu Wu, MD",{"type":49,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"PRINCIPAL_INVESTIGATOR","San-Gang Wu","Dr.","100568092","phase-2-sbrt-combined-with-nimotuzumab-and-tislelizumab-for-oligoprogressive-recurrentmetastatic-nasopharyngeal-carcinoma-after-failure-of-immunotherapy-100568092",false,"NCT06676722","SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent\u002FMetastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy","A Prospective, Single-Arm, Exploratory Study of SBRT Combined With Nimotuzumab and Sequential Tislelizumab for Oligoprogressive Distant Recurrent\u002FMetastatic Nasopharyngeal Carcinoma After Failure of First-Line Immunotherapy","1. Inclusion Criteria:\n\n   1.1. Pathologically confirmed non-keratinizing nasopharyngeal carcinoma; 1.2. Patients with recurrent\u002Fmetastatic nasopharyngeal carcinoma who have previously received first-line treatment including anti-PD-1 immune checkpoint inhibitor therapy and failed, presenting with oligoprogression (1-5 metastatic lesions); 1.3. Eligible to receive SBRT, Tislelizumab, and Nimotuzumab; 1.4. No history of other malignant tumors; 1.5. Male or female, aged 18-75 years; 1.6. Liver function: Total bilirubin ≤ Upper Limit of Normal (ULN); AST and ALT ≤ 2.5 × ULN; Alkaline phosphatase ≤ 5 × ULN; 1.7. Renal function: Creatinine clearance ≥ 80 mL\u002Fmin; 1.8. Hematological tests: Absolute neutrophil count (ANC) ≥ 2 × 109\u002FL, platelet count ≥ 100 × 109\u002FL, and hemoglobin ≥ 9 g\u002FdL; 1.9. No severe dysfunction of heart, lung, and other vital organs; 1.10. Performance Status (PS) score ≤ 2.\n2. Exclusion Criteria:\n\n2.1. Disagree to sign the informed consent form; 2.2. Patients who cannot comply with regular follow-ups due to psychological, social, family, or geographical reasons; 2.3. Receiving other experimental treatments as part of a clinical study (during the treatment period of the clinical study); 2.4. Severe, uncontrolled infections or medical conditions; 2.5. Major organ dysfunction, decompensated heart, lung, kidney, or liver failure, unable to tolerate radiotherapy or immunotherapy; 2.6. Factors affecting drug administration, distribution, metabolism, or excretion, such as mental abnormalities, central nervous system abnormalities, chronic diarrhea, ascites, pleural effusion, etc.; 2.7. Overexposure to glucocorticoids within 2 weeks before immunotherapy; 2.8. Long-term use of immunosuppressive agents after organ transplantation.",true,"ALL","18 Years","75 Years",{"count":64,"type":65},20,"ESTIMATED","INTERVENTIONAL",[68],"PHASE2","This study is a single-arm, open-label, prospective, and exploratory investigation aimed at examining the short-term efficacy, specifically the objective response rate (ORR), of SBRT combined with Nimotuzumab followed by Tislelizumab in patients with recurrent\u002Fmetastatic nasopharyngeal carcinoma who have experienced oligoprogression (1-5 metastatic lesions) after immunotherapy.",[71,72,73],"Nasopharyngeal Cancinoma (NPC)","SBRT","Immunotherapy","2025-06-30",{"date":76,"type":77},"2025-07-01","ACTUAL",{"date":79,"type":77},"2024-11-05",{"date":81,"type":65},"2027-12-31",{"name":5,"class":6},2]